The BRCA1 coiled-coil domain is dispensable for suppression of tandem duplications and tolerance of FANCM loss
BRCA1-linked cancers contain abundant ~10 kb 'Group 1' tandem duplications (TDs). Group 1 TDs form at a Tus/Ter replication-fork barrier in DNA-end resection-defective mouse embryonic stem (mES) cells lacking Brca1 exon 11. To elucidate how BRCA1 suppresses Group 1 TDs, we analyzed Brca1 coiled-coil (CC)-domain mutants-separation-of-function alleles impaired for homologous recombination (HR) through loss of PALB2-binding and RAD51-loading functions but competent for DNA-end resection. Notably, Brca1 CC mutants retain the ability to suppress Group 1 TDs in the Tus/Ter system and in a mouse model of Brca1-linked mammary tumorigenesis. These data suggest that Brca1 CC domain-mutant cancers follow a path of tumorigenesis distinct from that of other Brca1-linked cancers. FANCM is a TD co-suppressor, loss of which is synthetic lethal/sick in Brca1 exon 11-deleted cells. In contrast, Fancm deletion unexpectedly improves the growth of Brca1 CC mutant and Brca2 mutant mES cells. Thus, Group 1 tandem duplication formation and Fancm synthetic lethality are linked phenotypes, potentially related to defective BRCA1-mediated DNA end resection but genetically separable from BRCA1/PALB2-mediated RAD51 loading.
Authors
- Namrata M. Nilavar (ORCID: https://orcid.org/0000-0001-6081-0513)
- Ralph Scully (ORCID: https://orcid.org/0000-0002-5064-0175)
- Jos Jonkers (ORCID: https://orcid.org/0000-0002-9264-9792)
- Daniel Nguyen (ORCID: https://orcid.org/0000-0003-3157-8107)
- Alberto Marín-González (ORCID: https://orcid.org/0000-0002-9076-1270)
- Francesca Menghi (ORCID: https://orcid.org/0000-0002-7209-251X)
- Bing Xia (ORCID: https://orcid.org/0000-0003-3259-6139)
- Ellen Wientjens
- Nicholas A Willis
- Edison T Liu
Institutions
- Rutgers, The State University of New Jersey (US)
- Beth Israel Deaconess Medical Center (US)
- Howard Hughes Medical Institute (US)
- Cancer Research Institute (US)
- The Netherlands Cancer Institute (NL)
- Oncode Institute (NL)
- Jackson Laboratory (US)
- Intellia Therapeutics (United States) (US)
- The Jackson Laboratory for Genomic Medicine (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- The EMBO Journal
- Published
- 2026-09-18
- DOI
- https://doi.org/10.1038/s44318-026-00913-x
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Cancer Society
- Lundbeckfonden
- KWF Kankerbestrijding
- Oncode Institute
- National Cancer Institute